Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 11/20 | 1.00 |
| ▸ | NPC1 | O15118 | 10/20 | 1.00 |
| ▸ | MEN1 | O00255 | 10/20 | 1.00 |
| ▸ | RAB9A | P51151 | 9/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 4/20 | 1.00 |
| ▸ | NFKB2 | Q00653 | 4/20 | 1.00 |
| ▸ | RELA | Q04206 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | PPP1CA | P62136 | 2/20 | 1.00 |
| ▸ | ALPL | P05186 | 1/20 | 1.00 |
| ▸ | KCNN1 | Q92952 | 2/20 | 0.74 |
| ▸ | KCNN2 | Q9H2S1 | 2/20 | 0.74 |
| ▸ | KCNN3 | Q9UGI6 | 2/20 | 0.74 |
| ▸ | MBD2 | Q9UBB5 | 2/20 | 0.74 |
| ▸ | MECP2 | P51608 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30745771 | 0.86 | KCNN1 (1.00) | KMT2ANPC1MEN1RAB9AMAPT | |
| SCHEMBL5155715 | 0.86 | KCNN1 (1.00) | KMT2ANPC1MEN1RAB9AMAPT | |
| SCHEMBL6368980 | 0.84 | KCNN1 (0.75) | KMT2ANPC1MEN1RAB9AMAPT | |
| SCHEMBL7678939 | 0.82 | MAPT (0.81) | KMT2ANPC1MEN1RAB9AMAPT | |
| SCHEMBL15993250 | 0.81 | KMT2A (0.68) | KMT2ANPC1MEN1RAB9AMAPT | |
| Bromide SCHEMBL7673197 | 0.81 | MAPT (0.79) | KMT2ANPC1MEN1RAB9AMAPT | |
| SCHEMBL14742676 | 0.81 | RAB9A (0.82) | KMT2ANPC1MEN1RAB9AMAPT | |
| SCHEMBL14742535 | 0.80 | SLC2A1 (1.00) | KMT2ANPC1MEN1RAB9AMAPT | |
| SCHEMBL5157963 | 0.80 | KCNN1 (1.00) | KMT2ANPC1MEN1RAB9AMAPT | |
| SCHEMBL29601716 | 0.80 | KCNN1 (1.00) | KMT2ANPC1MEN1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090053192-A1 | TISSUE-NONSPECIFIC ALKALINE PHOSPHATASE (TNAP) ACTIVATORS AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-02-26 | — | — | US | claimed |
| US-10221169-B2 | Substituted aminothiazoles for the treatment of tuberculosis | THE BROAD INSTITUTE, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10221169-B2 | Substituted aminothiazoles for the treatment of tuberculosis | THE BROAD INSTITUTE, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170305895-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | THE GENERAL HOSPITAL CORPORATION | 2017-10-26 | — | — | US | disclosed |
| US-20170305895-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | THE GENERAL HOSPITAL CORPORATION | 2017-10-26 | — | — | US | disclosed |
| US-20170305895-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | THE GENERAL HOSPITAL CORPORATION | 2017-10-26 | — | — | US | disclosed |
| US-20160031874-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-04 | — | — | US | disclosed |
| US-20160031874-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-04 | — | — | US | disclosed |
| US-20160031874-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-04 | — | — | US | disclosed |
| WO-2014159938-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | THE BROAD INSTITUTE, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2009042294-A2 | TISSUE-NONSPECIFIC ALKALINE PHOSPHATASE (TNAP) ACTIVATORS AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-04-02 | — | — | WO | disclosed |
| US-20090053192-A1 | TISSUE-NONSPECIFIC ALKALINE PHOSPHATASE (TNAP) ACTIVATORS AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090053192-A1 | TISSUE-NONSPECIFIC ALKALINE PHOSPHATASE (TNAP) ACTIVATORS AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090053192-A1 | TISSUE-NONSPECIFIC ALKALINE PHOSPHATASE (TNAP) ACTIVATORS AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305895-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | AADAT, ABAT, AASDHPPT | KMT2A 1460/4885NPC1 2775/4885MEN1 3984/4885 |
| US-20160031874-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | ABAT, AADAT, AASDHPPT | KMT2A 2026/4885NPC1 2013/4885MEN1 4122/4885 |
| US-20090053192-A1 | TISSUE-NONSPECIFIC ALKALINE PHOSPHATASE (TNAP) ACTIVATORS AND USES THEREOF | ALPL, ALPP, ACP3 | KMT2A 3199/4885NPC1 3610/4885MEN1 4325/4885 |
| US-10221169-B2 | Substituted aminothiazoles for the treatment of tuberculosis | AADAT, ABAT, AASDHPPT | KMT2A 1460/4885NPC1 2775/4885MEN1 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.